Literature DB >> 29389229

Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out.

Rune A W van de Wetering1, Stefan Sleijfer1, Darren R Feldman1, Samuel A Funt1, George J Bosl1, Ronald de Wit1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29389229      PMCID： PMC6804842          DOI： 10.1200/JCO.2017.76.5610

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  21 in total

1.  Active surveillance is the preferred approach to clinical stage I testicular cancer.

Authors:  Craig R Nichols; Bruce Roth; Peter Albers; Lawrence H Einhorn; Richard Foster; Siamak Daneshmand; Michael Jewett; Padraig Warde; Christopher J Sweeney; Clair Beard; Tom Powles; Scott Tyldesley; Alan So; Christopher Porter; Semra Olgac; Karim Fizazi; Brandon Hayes-Lattin; Peter Grimison; Guy Toner; Richard Cathomas; Carsten Bokemeyer; Christian Kollmannsberger
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

2.  Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328).

Authors:  William G Jones; Sophie D Fossa; Graham M Mead; J Trevor Roberts; Michael Sokal; Alan Horwich; Sally P Stenning
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

3.  Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA).

Authors:  T Tandstad; O Ståhl; O Dahl; H S Haugnes; U Håkansson; Å Karlsdottir; A Kjellman; C W Langberg; A Laurell; J Oldenburg; A Solberg; K Söderström; U Stierner; E Cavallin-Ståhl; R Wahlqvist; N Wall; G Cohn-Cedermark
Journal:  Ann Oncol       Date:  2016-04-06       Impact factor: 32.976

4.  Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma.

Authors:  Stefanie Fischer; Torgrim Tandstad; Matthew Wheater; Emilio Porfiri; Aude Fléchon; Jorge Aparicio; Dirk Klingbiel; Breda Skrbinc; Umberto Basso; Jonathan Shamash; Anja Lorch; Klaus-Peter Dieckmann; Gabriella Cohn-Cedermark; Olof Ståhl; Caroline Chau; Edurne Arriola; Kalena Marti; Paul Hutton; Brigitte Laguerre; Pablo Maroto; Jörg Beyer; Silke Gillessen
Journal:  J Clin Oncol       Date:  2016-11-28       Impact factor: 44.544

5.  Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study.

Authors:  Jorge Aparicio; Pablo Maroto; Xavier García del Muro; Josep Gumà; Alfonso Sánchez-Muñoz; Mireia Margelí; Montserrat Doménech; Romá Bastús; Antonio Fernández; Marta López-Brea; Josefa Terrassa; Andrés Meana; Purificación Martínez del Prado; Javier Sastre; Juan J Satrústegui; Regina Gironés; Lidia Robert; José R Germà
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

6.  Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J Oldenburg; S D Fosså; J Nuver; A Heidenreich; H-J Schmoll; C Bokemeyer; A Horwich; J Beyer; V Kataja
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

7.  Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

Authors:  J Aparicio; P Maroto; X García del Muro; A Sánchez-Muñoz; J Gumà; M Margelí; A Sáenz; N Sagastibelza; D Castellano; J A Arranz; D Hervás; R Bastús; A Fernández-Aramburo; J Sastre; J Terrasa; M López-Brea; J Dorca; D Almenar; J Carles; A Hernández; J R Germà
Journal:  Ann Oncol       Date:  2014-09-10       Impact factor: 32.976

8.  Surveillance following orchidectomy for stage I seminoma of the testis.

Authors:  H von der Maase; L Specht; G K Jacobsen; A Jakobsen; E L Madsen; M Pedersen; M Rørth; H Schultz
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

9.  The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis.

Authors:  T Powles; D Robinson; J Shamash; H Moller; N Tranter; T Oliver
Journal:  Ann Oncol       Date:  2007-11-28       Impact factor: 32.976

Review 10.  Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel.

Authors:  Joost L Boormans; Javier Mayor de Castro; Lorenzo Marconi; Yuhong Yuan; M Pilar Laguna Pes; Carsten Bokemeyer; Nicola Nicolai; Ferran Algaba; Jan Oldenburg; Peter Albers
Journal:  Eur Urol       Date:  2017-11-20       Impact factor: 20.096
View more
  3 in total

1.  Controversies in the management of stage I seminoma: adjuvant carboplatin revisited.

Authors:  J Aparicio; J Terrasa
Journal:  Clin Transl Oncol       Date:  2018-07-10       Impact factor: 3.405

2.  [Risk of second malignancies after platinum-based chemotherapy of testicular cancer].

Authors:  David Utz; Arndt-Christian Müller
Journal:  Strahlenther Onkol       Date:  2019-02       Impact factor: 3.621

3.  Clinical implications of the American Joint Committee on Cancer (AJCC) 8th edition update in seminoma pT1 subclassification.

Authors:  Mário Fontes-Sousa; João Lobo; Helena Magalhães; João Cassis; Mariana Malheiro; Sância Ramos; Rui Henrique; Ana Martins; Maria Joaquina Maurício
Journal:  BMC Urol       Date:  2020-08-20       Impact factor: 2.264
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.